ANMCO Position paper : Use of sacubitril/valsartan in hospitalized patients with acute heart failure
Sacubitril/valsartan (S/V) has been shown to reduce the risk of cardiovascular death or heart failure hospitalization and improve symptoms in chronic heart failure with reduced ejection fraction compared to enalapril. After 7 years since the publication of the results of PARADIGM-HF, further insight has been gained with potential new indications. Two prospective randomized multicenter studies (PIONEER-HF and TRANSITION) in patients hospitalized for acute heart failure (AHF) have shown an improved clinical outcome and biomarker profile as compared to enalapril, and good tolerability, safety and feasibility of initiating in-hospital administration of S/V. Furthermore, some studies have highlighted the favorable effects of S/V in attenuating adverse myocardial remodeling, supporting an early benefit after treatment. Observational data from non-randomized studies in AHF report that in-hospital and pre-discharge prescription of evidence-based drugs associated with better survival still remains suboptimal. Additionally, the COVID-19 pandemic has also negatively impacted on outpatient activities. Therefore, hospitalization, a real crossroads in the history of heart failure, must become a management and therapeutic opportunity for our patients. The objective of this ANMCO position paper is to encourage and facilitate early S/V administration in stabilized patients during hospitalization after an AHF episode, with the aim of improving care efficiency and clinical outcome.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Giornale italiano di cardiologia (2006) - 22(2021), 10 vom: 11. Okt., Seite 854-860 |
| Sprache: |
Italienisch |
|---|
| Weiterer Titel: |
Position paper ANMCO: Utilizzo di sacubitril/valsartan nel paziente ricoverato con scompenso cardiaco acuto |
|---|
| Beteiligte Personen: |
Di Tano, Giuseppe [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
80M03YXJ7I |
|---|
| Anmerkungen: |
Date Completed 15.10.2021 Date Revised 15.10.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1714/3666.36517 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331117568 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331117568 | ||
| 003 | DE-627 | ||
| 005 | 20231225212745.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||ita c | ||
| 024 | 7 | |a 10.1714/3666.36517 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1103.xml |
| 035 | |a (DE-627)NLM331117568 | ||
| 035 | |a (NLM)34570120 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ita | ||
| 100 | 1 | |a Di Tano, Giuseppe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ANMCO Position paper |b Use of sacubitril/valsartan in hospitalized patients with acute heart failure |
| 246 | 3 | 3 | |a Position paper ANMCO: Utilizzo di sacubitril/valsartan nel paziente ricoverato con scompenso cardiaco acuto |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.10.2021 | ||
| 500 | |a Date Revised 15.10.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Sacubitril/valsartan (S/V) has been shown to reduce the risk of cardiovascular death or heart failure hospitalization and improve symptoms in chronic heart failure with reduced ejection fraction compared to enalapril. After 7 years since the publication of the results of PARADIGM-HF, further insight has been gained with potential new indications. Two prospective randomized multicenter studies (PIONEER-HF and TRANSITION) in patients hospitalized for acute heart failure (AHF) have shown an improved clinical outcome and biomarker profile as compared to enalapril, and good tolerability, safety and feasibility of initiating in-hospital administration of S/V. Furthermore, some studies have highlighted the favorable effects of S/V in attenuating adverse myocardial remodeling, supporting an early benefit after treatment. Observational data from non-randomized studies in AHF report that in-hospital and pre-discharge prescription of evidence-based drugs associated with better survival still remains suboptimal. Additionally, the COVID-19 pandemic has also negatively impacted on outpatient activities. Therefore, hospitalization, a real crossroads in the history of heart failure, must become a management and therapeutic opportunity for our patients. The objective of this ANMCO position paper is to encourage and facilitate early S/V administration in stabilized patients during hospitalization after an AHF episode, with the aim of improving care efficiency and clinical outcome | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Aminobutyrates |2 NLM | |
| 650 | 7 | |a Angiotensin Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Biphenyl Compounds |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a Tetrazoles |2 NLM | |
| 650 | 7 | |a Valsartan |2 NLM | |
| 650 | 7 | |a 80M03YXJ7I |2 NLM | |
| 650 | 7 | |a sacubitril and valsartan sodium hydrate drug combination |2 NLM | |
| 650 | 7 | |a WB8FT61183 |2 NLM | |
| 700 | 1 | |a Di Lenarda, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Iacoviello, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Oliva, Fabrizio |e verfasserin |4 aut | |
| 700 | 1 | |a Urbinati, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Aspromonte, Nadia |e verfasserin |4 aut | |
| 700 | 1 | |a Cipriani, Manlio |e verfasserin |4 aut | |
| 700 | 1 | |a Caldarola, Pasquale |e verfasserin |4 aut | |
| 700 | 1 | |a Murrone, Adriano |e verfasserin |4 aut | |
| 700 | 1 | |a Gulizia, Michele Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Colivicchi, Furio |e verfasserin |4 aut | |
| 700 | 1 | |a Gabrielli, Domenico |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Giornale italiano di cardiologia (2006) |d 2006 |g 22(2021), 10 vom: 11. Okt., Seite 854-860 |w (DE-627)NLM16119561X |x 1972-6481 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2021 |g number:10 |g day:11 |g month:10 |g pages:854-860 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1714/3666.36517 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2021 |e 10 |b 11 |c 10 |h 854-860 | ||